Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Leases (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Operating Leases data on record, last reported at $11.9 million in Q4 2025.

  • For Q4 2025, Operating Leases rose 17.12% year-over-year to $11.9 million; the TTM value through Dec 2025 reached $11.9 million, up 17.12%, while the annual FY2025 figure was $11.9 million, 17.12% up from the prior year.
  • Operating Leases reached $11.9 million in Q4 2025 per APLS's latest filing, down from $13.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $19.9 million in Q1 2021 and bottomed at $8.3 million in Q2 2025.
  • Average Operating Leases over 5 years is $13.5 million, with a median of $12.6 million recorded in 2023.
  • Peak YoY movement for Operating Leases: surged 78.16% in 2021, then decreased 28.83% in 2023.
  • A 5-year view of Operating Leases shows it stood at $17.1 million in 2021, then decreased by 15.98% to $14.4 million in 2022, then fell by 20.19% to $11.5 million in 2023, then decreased by 10.94% to $10.2 million in 2024, then rose by 17.12% to $11.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $11.9 million in Q4 2025, $13.7 million in Q3 2025, and $8.3 million in Q2 2025.